Xencor to Present at Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
-
TD Cowen 44th Annual Health Care Conference
Date: Wednesday, March 6, 2024
Presentation Time: 12:50 p.m. ET / 9:50 a.m. PT
Location:Boston
-
Leerink Partners Global Biopharma Conference
Date: Tuesday, March 12, 2024
Presentation Date/Time: Wednesday, March 13, 2024, 9:20 a.m. ET / 6:20 a.m. PT
Location:Miami
-
Jefferies Biotech on the Bay Summit
Date: Wednesday, March 13, 2024
Location:Miami
-
Barclays Global Healthcare Conference
Date: Thursday, March 14, 2024
Presentation Time: 11:15 a.m. ET / 8:15 a.m. PT
Location:Miami
Live webcasts of the Cowen, Leerink and Barclays presentations will be available under “Events & Presentations” in the Investors section of the Company’s website located at www.xencor.com. Replays of the events will be available on the Xencor website for at least 30 days following the presentations.
About Xencor
Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and other serious diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and three XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein's structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240228121602/en/
Charles Liles
cliles@xencor.com
(626) 737-8118
Source: Xencor, Inc.